Skip to main content

Table 3 Adverse events with an incidence ≥ 5% in either treatment group over 24 weeks (APT set)

From: Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

 

MOD-SEV subgroupa

MOD subgroupb

Adverse event

Memantine added to donepezil

( n = 269)

Placebo added to donepezil

( n = 251)

Memantine added to donepezil

( n = 190)

Placebo added to donepezil

( n = 185)

Patients with AEs

206 (76.6)

186 (74.1)

144 (75.8)

136 (73.5)

   Dizziness

20 (7.4)

19 (7.6)

17 (8.9)

16 (8.6)

   Agitation

17 (6.3)*

29 (11.6)

9 (4.7)*

19 (10.3)

   Confusional state

15 (5.6)

6 (2.4)

-

-

   Diarrhoea

14 (5.2)

21 (8.4)

12 (6.3)

14 (7.6)

   Nasopharyngitis

14 (5.2)

6 (2.4)

-

-

   Falls

11 (4.1)

15 (6.0)

10 (5.3)

11 (5.9)

   Urinary tract infection

-

-

10 (5.3)

8 (4.3)

   Depression

-

-

6 (3.2)

11 (5.9)

  1. Data are number (%). aModerate to severe AD (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day). bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10 mg/day). *P < 0.05 versus placebo added to donepezil. APT, all-patients-treated; AE, adverse event; '-' denotes AEs with an incidence < 5% in both treatment groups in the respective severity subgroup.
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193